Juno Therapeutics and WuXi AppTec announce new company
New company to develop novel cell-based cancer immunotherapies in China.
Juno Therapeutics and WuXi AppTec have started a new company in China. JW Biotechnology (Shanghai) Co., Ltd’s mission is to build China’s leading cell therapy company by leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. James Li, M.D., formerly a Kleiner Perkins partner and General Manager of Amgen China, and a JW Biotechnology (Shanghai) Co., Ltd co-founder, has been appointed CEO of JW Biotechnology (Shanghai) Co., Ltd.
“Juno’s goal is to create novel immuno-oncology therapies to treat cancer patients around the world across a range of cancer types. Over 2.5 million people in China die annually from cancer, making it imperative for us to find an effective structure to reach these patients,” said Hans Bishop, Juno’s President and CEO. “JW Biotechnology (Shanghai) Co., Ltd, with Dr James Li as CEO,will be able to draw on a diverse set of expertise from our company. WuXi AppTec’s track record of leadership and excellence in the Chinese pharmaceutical R&D sector will be key to develop and commercialize Juno’s transformational technologies for patients in this important market.”
“WuXi is very delighted to work with Juno Therapeutics, a world leader in immuno-oncology, to bring highly innovative cell therapy products to patients in China through JW Biotechnology (Shanghai) Co., Ltd,” said Dr Ge Li, Chairman and CEO of WuXi AppTec. “The Chinese government’s regulatory reforms are expected to drive growth and demand for quality medicines that target major unmet medical needs in China, and our mission is to enable the development and commercialization of therapeutics in China through WuXi’s open-access R&D and manufacturing platform, and strategic partnerships with leading organizations worldwide.”
”JW Biotechnology (Shanghai) Co., Ltd will leverage Juno’s expertise in cell therapy technologies and WuXi AppTec’s excellence in contract services, and collaborate broadly with Chinese medical communities and government regulators to develop cell therapies that will deliver cutting-edge cancer treatments to Chinese patients. These novel technologies offer a unique opportunity that holds the potential to save lives while transforming the treatment of cancer,” said Dr James Li, CEO of JW Biotechnology (Shanghai)Co., Ltd.
Juno and WuXi AppTec have equal initial ownership in JW Biotechnology (Shanghai) Co., Ltd, which after meeting certain conditions will have access to licensing product candidates from Juno’s pipeline for development and commercialization in China. In exchange, Juno will receive an upfront payment in equity, milestone payments, and royalties on any net sales. Dr Ge Li will serve as Chairman of the Board of JW Biotechnology (Shanghai) Co., Ltd, and the remainder of the Board of Directors will initially include Dr James Li, Hans Bishop, Steve Harr, M.D., Juno’s Chief Financial Officer and Head of Corporate Development, and Edward Hu, WuXi AppTec’s Chief Financial Officer and Chief Investment Officer.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance